Statin prescription among patients with type 2 diabetes in Botswana : findings and implications
| dc.contributor.author | Mwita, Julius Chacha | en_ZA |
| dc.contributor.author | Godman, Brian | en_ZA |
| dc.contributor.author | Esterhuizen, Tonya M. | en_ZA |
| dc.date.accessioned | 2020-03-16T09:39:05Z | |
| dc.date.available | 2020-03-16T09:39:05Z | |
| dc.date.issued | 2020-03-10 | |
| dc.date.updated | 2020-03-15T04:28:49Z | |
| dc.description | CITATION: Mwita, J. C., Godman, B. & Esterhuizen, T. M. 2020. Statin prescription among patients with type 2 diabetes in Botswana : findings and implications. BMC Endocrine Disorders, 20:36, doi:10.1186/s12902-020-0516-7. | |
| dc.description | The original publication is available at https://bmcendocrdisord.biomedcentral.com | |
| dc.description.abstract | Background: There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. Methods: The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescriptions. Results: Overall, 477 (95.4%) participants were eligible for a statin prescription. Clinicians prescribed statins in 217 (45.5%) of eligible participants, and only one (4.4%) ineligible participant. The probability of a statin prescription was higher in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17–1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00–1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06–1.74). Conclusion: A large proportion with type 2 diabetes in Gaborone is not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescriptions. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations. | en_ZA |
| dc.description.version | Publisher's version | |
| dc.format.extent | 9 pages | |
| dc.identifier.citation | Mwita, J. C., Godman, B. & Esterhuizen, T. M. 2020. Statin prescription among patients with type 2 diabetes in Botswana : findings and implications. BMC Endocrine Disorders, 20:36, doi:10.1186/s12902-020-0516-7. | |
| dc.identifier.issn | 1472-6823 (online) | |
| dc.identifier.other | doi:10.1186/s12902-020-0516-7 | |
| dc.identifier.uri | https://doi.org/10.1186/s12902-020-0516-7 | |
| dc.identifier.uri | http://hdl.handle.net/10019.1/107620 | |
| dc.language.iso | en | |
| dc.publisher | BioMed Central | |
| dc.rights.holder | Authors retain copyright | |
| dc.subject | Non-insulin-dependent diabetes -- Patients -- Gaborone (Botswana) | en_ZA |
| dc.subject | Statins (Cardiovascular agents) -- Prescribing -- Gaborone (Botswana) | en_ZA |
| dc.title | Statin prescription among patients with type 2 diabetes in Botswana : findings and implications | en_ZA |
| dc.type | Article |